The headline reads as positive (76% confidence from the FinBERT financial-language model), so the stock went through the full analysis. The broader analysis agrees with the good news.
Stocks › UTHR
United Therapeutics Corporation (UTHR) stock analysis
BUY 46% confidence · analysed Oct 14, 2026
On Oct 14, 2026, our model rated United Therapeutics Corporation (UTHR) BUY with 46% confidence at a price of $543.40. That means most of the technical, fundamental, money-flow and news signals point to upside.
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
Market cap23.31B
Analysed price$543.40
Technical picture
The 14-day RSI is 63, showing healthy upward momentum without being stretched.
MACD is above its signal line, a sign that short-term momentum is turning up.
The price is above both its 50-day and 200-day moving averages, the classic picture of an uptrend.
Volume is only 0.5x its 20-day average; light trading makes the latest move less convincing.
Trend structure and money flow
Market structure: ranging / no clear structure.
The most recent swing high is $609.35 and the swing low is $409.07; traders often treat these as resistance and support.
Price is sitting in a bullish order block, a zone where large buyers stepped in before.
Fundamentals
The PEG ratio is 2.22, which looks expensive relative to its growth.
The company reports a profit margin of 41.6% and revenue growth of -1.9%.
In its latest quarter it earned $7.27 per share, which beat the $6.86 analysts expected, with revenue -1.9% year over year.
Wall Street's average rating is 1.9 on a 1 (strong buy) to 5 (sell) scale, roughly a "buy", with an average price target of $651.86.
The next earnings report is expected around Oct 28, 2026; prices often move sharply around earnings.
Trade plan from the model
The model's long / bullish plan uses an entry near $537.64, a target of $619.80 (+15.3%) and a stop-loss at $489.56 (-8.9%).
That is a reward-to-risk ratio of about 1.7 to 1: the potential gain is larger than the potential loss.
The plan has a time limit: reassess by Oct 27, 2026 whatever the price does.
Entry$537.64
Target$619.80
Stop-loss$489.56
Reassess byOct 27, 2026
The model's one-paragraph read
Leans BUY — composite score +0.46 (BUY). Technicals: RSI 63.21, MACD bullish, price above SMA50. Fundamentals: PEG 2.22, margin 41.6%, revenue growth -1.9%. Financial results: YoY revenue -1.9%, last EPS surprise +6.0%, next earnings 2026-10-28. Smart Money Concepts: ranging / no clear structure, price retesting a bullish order block, price retesting a bearish order block. FinGPT news read: positive. Memory: 2 prior look(s). Suggested levels: entry $537.64, target $619.8, stop-loss $489.56, exit by 2026-10-27 (exit before next earnings (2026-10-28) -- this signal doesn't price in that report).
Past ratings for UTHR
| Date | Verdict | Confidence | Price | Move since | |
|---|---|---|---|---|---|
| Oct 14, 2026 | BUY | 46% | $543.40 | — |
"Move since" compares each call's price with the latest analysed price.
Recent news on UTHR
Oct 14, 2026 · Liquidia shares surge to 5-month high premarket on United Therapeutics settlement
Oct 13, 2026 · Liquidia stock surges 40% on $380.7M litigation settlement with UTHR
The headline reads as positive (82% confidence from the FinBERT financial-language model), so the stock went through the full analysis. The rest of the picture is mixed, so the headline alone is not enough for a clear call.
- Oct 14, 2026: LQDA Stock Rockets 40% Today BTIG Calls United Therapeutics Settlement Better Than Best-Case Scenario (Stocktwits)
- Oct 14, 2026: Liquidia shares surge to 5-month high premarket on United Therapeutics settlement (Investing.com)
- Oct 13, 2026: Liquidia stock surges 40% on $380.7M litigation settlement with UTHR (Investing.com)
Other Healthcare stocks we cover
ZBH · ALC · AMGN · AMRX · ANIP · ARWR · ASTH · ATEC · ATRC · BCRX · BDX · BIIB
Frequently asked questions
Is UTHR a buy right now?
As of Oct 14, 2026, our automated model rates United Therapeutics Corporation (UTHR) BUY with 46% confidence: most of the technical, fundamental, money-flow and news signals point to upside. This is a model output for education, not personal investment advice.
What is the price target for UTHR?
The model's most recent plan targets $619.80 with a stop-loss at $489.56, from an entry near $537.64.
When does United Therapeutics Corporation report earnings next?
The next earnings report is expected around Oct 28, 2026.
What does a BUY rating mean?
A BUY rating means most of the technical, fundamental, money-flow and news signals point to upside.
For information and education only. Not investment advice. Ratings are produced by an automated model, can be wrong, and may be out of date. Do your own research; you can lose money investing. The site's author may hold positions in stocks discussed here.